Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel

BJU International

Volumn 100, Issue 4, 2007, Pages 775-779

  Petrioli, Roberto ^a   Pascucci, Alessandra ^a   Francini, Edoardo ^a   Marsili, Stefania ^a   Sciandivasci, Angela ^a   De Rubertis, Giovanni ^a   Barbanti, Gabriele ^a   Manganelli, Antonio ^a   Salvestrini, Francesco ^a   Francini, Guido ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Calcitriol; Docetaxel; Hormone refractory; Prostate cancer

Indexed keywords

CALCITRIOL; DEXAMETHASONE; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG MEGADOSE; DRUG TOLERABILITY; DRY EYE; DYSPNEA; EPISTAXIS; FATIGUE; HUMAN; HYPERCALCEMIA; HYPOPHOSPHATEMIA; MALE; METASTASIS; MYALGIA; NAIL COLOR DEFECT; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTATE CANCER; REFRACTORY PERIOD; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCITRIOL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 34548440846     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07019.x     Document Type: Article

References (26)

1. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 351 : 1502 12
2. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 351 : 1513 20
3. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003 21 : 123 8
4. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-Dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994 54 : 805
5. Simboli-Campbell M, Narvaez CJ, Tenniswood M, Welsh J. 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 1996 58 : 367 76
6. Berry W, Dakhil S, Gregurich MA et al. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001 28 (Suppl. 15 8 15
7. Beer TM. ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU Int 2005 96 : 508 13
8. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evacuate the response to treatment in solid tumors. J Natl Cancer Inst 2000 92 : 205 61
9. Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 2005 23 : 8247 52
10. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996 14 : 1756 64
11. Michels JE, Montemurro T, Kollmannsberger C, Murray N, Chi KN. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer (HRPC): does sequence matter? ASCO 2005 : 4611
12. Oh WK, Manola J, Babcic V, Harnam N, Kantoff PW. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 2006 67 : 1235 40
13. Petrioli R, Fiaschi AI, Pozzessere D et al. Weekly epirubicin in patients with hormone-resistant prostate cancer. Br J Cancer 2002 87 : 720 5
14. Petrioli R, Paolelli L, Francini E, Manganelli A, Salvestrini F, Francini G. Weekly docetaxel and epirubicin in the treatment of advanced hormone-refractory prostate cancer. Urology 2007 69 : 142 6
15. Daliani DD, Assikis V, Tu SM et al. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer 2003 97 : 561 7
16. Abratt RP, Brune D, Dimopoulos MA et al. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone refractory prostate cancer. Ann Oncol 2004 15 : 1582 4
17. El Demery M, Pouessel D, Avances C et al. What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate? Prog Urol 2006 16 : 320 3
18. Odrazka K, Vaculikova M, Dolezel M et al. Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer? Oncol Rep 2005 14 : 1077 81
19. Sternberg CN. Satraplatin in the treatment of hormone-refractory prostate cancer. BJU Int 2005 96 : 990 4
20. Galsky MD, Small EJ, Oh WK et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005 23 : 1439 46
21. Tiffany NM, Ryan CV, Garzotto M, Wersinger EM, Beer TM. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. J Urol 2005 174 : 888 92
22. Beer TM, Ryan CW, Venner PM et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. J Clin Oncol 2007 25 : 669 74
23. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2004 94 : 1458 68
24. Muindi JR, Peng Y, Potter DM et al. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 2002 72 : 648 59
25. Morris MJ, Smaletz O, Solit D et al. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer 2004 100 : 1868 75
26. Engels FK, Verweij J. Docetaxel administration schedule. From fever to tears? A review of randomised studies. Eur J Cancer 2005 41 : 1117 26